AC Immune (NASDAQ:ACIU) Shares Cross Below 50-Day Moving Average – Should You Sell?

Posted by Brian Himes on Aug 6th, 2026

AC Immune (NASDAQ:ACIU – Get Free Report)’s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.39 and traded as low as $2.22. AC Immune shares last traded at $2.27, with a volume of 106,019 shares.

Analysts Set New Price Targets

ACIU has been the subject of several recent research reports. BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Wednesday. Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. Finally, HC Wainwright reiterated a “buy” rating on shares of AC Immune in a report on Wednesday, July 1st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $7.50.

Read Our Latest Stock Report on ACIU

AC Immune Stock Up 1.3%

The business’s fifty day moving average price is $2.37 and its two-hundred day moving average price is $2.77. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87. The firm has a market capitalization of $236.11 million, a P/E ratio of -4.30 and a beta of 1.59.

AC Immune (NASDAQ:ACIU – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The company had revenue of $18.67 million during the quarter, compared to analysts’ expectations of $10.92 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 94.52%. Equities analysts expect that AC Immune will post -0.84 earnings per share for the current fiscal year.

Insider Activity at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the completion of the sale, the chief executive officer owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ACIU. EFG International AG acquired a new stake in AC Immune in the fourth quarter worth about $41,000. Private Advisor Group LLC acquired a new position in shares of AC Immune during the third quarter valued at about $48,000. Sei Investments Co. purchased a new position in shares of AC Immune in the 2nd quarter valued at approximately $51,000. Goldman Sachs Group Inc. raised its position in shares of AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in AC Immune in the 3rd quarter worth approximately $63,000. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Company Profile

(Get Free Report)

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.